Dose-Dense Chemotherapy in Breast Cancer

Definition and Mechanism

Dose-dense chemotherapy involves shortening the interval between chemotherapy cycles while maintaining standard drug doses, supported by colony-stimulating factors (CSFs) to prevent severe neutropenia, based on the Norton-Simon hypothesis that maximal chemotherapy effectiveness occurs when scheduling corresponds to the period of most rapid tumor regrowth between cycles 1

Meta-analysis data demonstrate that dose-dense chemotherapy improves both disease-free survival (HR 0.83, 95% CI 0.73-0.94) and overall survival (HR 0.84, 95% CI 0.72-0.98) compared to conventional 3-week schedules 2
The SWOG S0221 trial showed that doxorubicin plus cyclophosphamide every 2 weeks followed by paclitaxel every 2 weeks achieved the highest overall survival compared to continuous or weekly schedules 1
Sequential epirubicin, paclitaxel, and cyclophosphamide every 2 weeks improved event-free survival and overall survival (OS HR 0.76, 95% CI 0.59-0.97) compared to conventional 3-week scheduling 2

The National Comprehensive Cancer Network recommends dose-dense doxorubicin and cyclophosphamide (AC) followed or preceded by paclitaxel (either weekly or biweekly) as a preferred regimen for adjuvant treatment of HER2-negative breast cancer, demonstrating a 26% reduction in hazard of recurrence and 31% reduction in hazard of death when given every 2 weeks with filgrastim support versus every 3 weeks 3
The American Society of Clinical Oncology guidelines state that dose-dense regimens with CSF support should only be used if supported by convincing efficacy data, with strong evidence supporting use in adjuvant treatment of high-risk breast cancer, and evidence quality is rated as HIGH for breast cancer with a STRONG strength of recommendation 1
The European Society for Medical Oncology guidelines suggest that the use of dose-dense schedules with G-CSF support should be considered particularly in highly proliferative tumors 4

G-CSF (filgrastim) support is essential and should be administered with each cycle to prevent severe neutropenia 1
Standard dose-dense regimen: AC (doxorubicin/cyclophosphamide) every 2 weeks × 4 cycles followed by paclitaxel every 2 weeks × 4 cycles, all with G-CSF support 3

The indication for dose-dense chemotherapy is independent of age, though elderly patients may require more careful monitoring and dose adjustments based on tolerance 6

The St. Gallen consensus panel was split on using dose-dense every-2-week AC/EC regimens with neoadjuvant pembrolizumab—30% supported the dose-dense fortnightly combination, while 38% noted lack of safety and efficacy data and were not inclined to use this approach with immunotherapy, as per the Annals of Oncology 7, 8

The NCCN-endorsed approach includes AC (doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m²) every 2 weeks × 4 cycles followed by paclitaxel every 2 weeks × 4 cycles, all with G-CSF support (category 1 evidence), according to the National Comprehensive Cancer Network 9

For Stage II-III Breast Cancer Requiring Neoadjuvant Therapy, the Annals of Oncology recommends using dose-dense AC every 2 weeks × 4 cycles followed by weekly paclitaxel × 12 cycles with G-CSF support for TNBC, and dose-dense AC/TH or TCH with pertuzumab for HER2-Positive disease 7, 8
For HR-Positive/HER2-Negative disease, consider dose-dense regimens for highly proliferative tumors, but recognize lower pCR rates, as suggested by the Annals of Oncology 10

The indication for dose-dense chemotherapy is independent of age, though elderly patients require careful monitoring and potential dose adjustments based on tolerance, according to the Annals of Oncology 11
In patients with cardiac risk factors or pre-existing cardiac disease, consider non-anthracycline regimens rather than dose-dense anthracycline-containing protocols, as recommended by the Annals of Oncology 10